$CLYM: Climb Bio Reports Positive Initial Phase 2 PrisMN Data for Budoprutug

$CLYM

$CLYM – Climb Bio Reports Positive Initial Phase 2 PrisMN Data for Budoprutug in pMN

Climb Bio, Inc.

2026-10-26 00:00:00 UTC · SEC_8K · All $CLYM

?? Positive AI Sentiment (+6.5 / 10)

Low dose (200 mg) achieved B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks.
Higher 600 mg dose demonstrated deeper peripheral B-cell depletion with acceptable tolerability.
Trial is ongoing with additional Phase 2 data expected in 2027.

Observed market reaction after signal

4h -6.48% · Peak +0.10%